NextCure, Inc. (NXTC) Form 10-Q — Aug 6, 2026
NextCure's Q2 2026 10-Q discloses substantial doubt about the company's ability to continue as a going concern, with $20.1 million in cash, cash equivalents and marketable securities expected to fund operations only into the fourth quarter of 2026. The clinical-stage biotech has an accumulated deficit of approximately $461 million and has never generated product revenue; Q2 net loss was $14.9 million, or $2.80 per share. On July 14, 2026, NextCure signed a definitive all-stock merger agreement with privately held Avere Therapeutics, under which the combined company will operate as Avere Therapeutics and trade on Nasdaq as AVRX.
Key figures
- Total Assets
- 22620000
- Cash Position
- $15.3 million cash and equivalents ($20.1 million including marketable securities)
- Shares Outstanding
- 4577359
- Cash runway
- into the fourth quarter of 2026
- Sim0505 phase1 orr
- 55% in evaluable gynecologic cancer patients (ASCO June 2026, 59 patients enrolled)
- Accumulated deficit
- 460668000
- Reverse split ratio
- 1:12 (effected July 14, 2025)
- Stockholders equity
- 12149000
- Lease termination fee
- $0.8 million (space reduced from ~69,296 to ~29,864 sq ft)
- Atm capacity wainwright
- $14.5 million (~$1.2 million raised in H1 2026)
- Asset impairment q2 2026
- 5077000
- Asset sale proceeds xcellon
- approximately $0.5 million
- Concurrent private placement
- approximately $320 million gross proceeds (Avere Therapeutics)
- Expected restructuring charges
- $2.4 million through October 31, 2026
- Minimum financing to close merger
- 150000000
- Gross equity raised since inception
- approximately $446 million
Price after filing
Close on the filing date to close N calendar days later (from $5.78). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.